Pages that link to "Q28206334"

The following pages link to Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine (Q28206334):

Displaying 21 items.

• Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers (Q24545856) (← links)
• (Q28161780) (redirect page) (← links)
• Low seroprevalent species D adenovirus vectors as influenza vaccines. (Q30353263) (← links)
• Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. (Q30360869) (← links)
• Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses (Q30377017) (← links)
• Needle-free influenza vaccination. (Q30394326) (← links)
• Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin (Q30401519) (← links)
• The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine (Q30404699) (← links)
• A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge (Q33360151) (← links)
• Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations (Q33586172) (← links)
• Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. (Q34621661) (← links)
• Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. (Q34768241) (← links)
• A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults (Q36116560) (← links)
• Induction of mucosal immunity through systemic immunization: Phantom or reality? (Q37130744) (← links)
• Immunosenescence and vaccination in nursing home residents (Q37367442) (← links)
• Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans (Q37423256) (← links)
• Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient. (Q42689593) (← links)
• An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits (Q46985623) (← links)
• Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine (Q47356431) (← links)
• A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. (Q54626497) (← links)
• A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus (Q91552268) (← links)